Follow Us
© 2026 Arizent. All rights reserved.
Glucagon-like peptide-1 (GLP-1) medications are doing more than transforming waistlines and blood sugar levels — they’re redefining corporate culture.
As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there’s the potential for improved employee health and productivity. On the other, employers face significant costs and implementation challenges.
As SVP and benefits consultant at Corporate Synergies, Harrison Newman is a trusted expert in employee benefits strategy with 16+ years of industry experience. He partners with HR and Finance leaders … Read full bio
For reprint and licensing requests for this article, click here.
The CEO of Connections Health Solutions explains how its crisis receiving centers can provide faster and more cost-efficient access to specialized care.
Industry leaders weigh the pros and cons of brokerage and advisory scale created through M&As vs. boutique shops.
Education and healthy work routines can help keep employees from experiencing chronic pain and lower productivity.
Less expensive options and customized levels of support can help employers make these medications work within their benefits plan.
When providers rush to high-cost procedures, plan sponsors are left subsidizing a bypass of the underlying metabolic issues that most determine pregnancy success.
